Greenberg brings 25 years of experience in the life sciences industry to InCarda. Credit: InCarda Therapeutics, Inc./Business Wire.

InCarda Therapeutics has announced the appointment of Dr Myles Greenberg as its new president and CEO.

Greenberg brings 25 years of experience in the life sciences industry to InCarda. His background includes roles as a CEO, venture investor and lead board member for companies developing new biopharmaceuticals, medical devices and healthcare technologies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Before joining InCarda, he served as an emergency physician and emergency department administrator at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Massachusetts, US.

He replaces interim CEO Carlos Schuler, a co-founder of the company, who will now take on the role of chief technology officer.

InCarda Therapeutics executive chairman Dan Welch stated: “Myles has an innate understanding of the challenges in properly treating cardiac arrythmias like paroxysmal atrial fibrillation [PAF], where underdiagnosis and undermanagement lead to disease progression, poor outcomes and significant strain on the healthcare system.

“We are confident that he is the right leader to build InCarda into a key driver of positive change that can address these challenges and improve the standard of care for physicians and patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Greenberg is set to lead the company as it progresses with the clinical development of its orally inhaled treatment, flecainide.

An antiarrhythmic medication, flecainide has been approved in the US for more than three decades for oral use in chronic treatment.

It is prescribed to decrease the risk of recurrent and symptomatic PAF in individuals who do not have structural heart disease.

Greenberg stated: “InCarda’s mission is to enable the growing number of PAF sufferers to take more control of their health by developing a product designed to allow patients eventually to treat their abnormal heart rhythm and symptoms at home. 

“If we are successful, we can improve patients’ quality of life and help them avoid unnecessary hospitalisations and other complications of their AF.”